Share This Article:

Acute ST-segment myocardial infarction—Evolution of treatment strategies

Abstract Full-Text HTML Download Download as PDF (Size:115KB) PP. 551-560
DOI: 10.4236/wjcd.2013.39087    3,425 Downloads   5,416 Views   Citations

ABSTRACT

The commonest cause of acute myocardial infarction involves the rupture or erosion of vulnerable atherosclerotic plaques followed by aggregation of platelets and subsequent thrombus formation, leading to partial or complete epicardial coronary arterial occlusion. Over the last 25 years, advancement in therapeutic options for acute myocardial infarction has resulted in substantial improvement in morbidity and mortality. As a result, the absolute risk reduction of in-hospital deaths for patients presenting with STEMI has been on the decline in the last decade. The focus of the treatment for acute myocardial infarction involves achieving epicardial and microvascular patency, prevention of recurrent ischaemic events while balancing the risk of bleeding. This involves antiplatelet and antithrombotic therapies or fibrinolytic agents when timely performance of primary percutaneous coronary intervention is not possible. We review the evolution of treatment strategies for STEMI that has contributed to the improvement in patient outcome.

 

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Wong, D. , Puri, R. , Psaltis, P. , Worthley, S. and Worthley, M. (2013) Acute ST-segment myocardial infarction—Evolution of treatment strategies. World Journal of Cardiovascular Diseases, 3, 551-560. doi: 10.4236/wjcd.2013.39087.

References

[1] Falk, E., Shah, P.K. and Fuster, V. (1995) Coronary plaque disruption. Circulation, 92, 657-671.
http://dx.doi.org/10.1161/01.CIR.92.3.657
[2] Libby, P. (2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 104, 365-372.
http://dx.doi.org/10.1161/01.CIR.104.3.365
[3] Reimer, K.A., Lowe, J.E., Rasmussen, M.M. and Jennings, R.B. (1977) The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation, 56, 786-794.
http://dx.doi.org/10.1161/01.CIR.56.5.786
[4] Gibson, C.M., Murphy, S.A., Kirtane, A.J., Giugliano, R.P., Cannon, C.P., Antman, E.M., et al. (2004) Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 44, 980-987. http://dx.doi.org/10.1016/j.jacc.2004.05.059
[5] De Luca, G., Suryapranata, H., Zijlstra, F., Van’t Hof, A.W., Hoorntje, J.C., Gosselink, A.T., et al. (2003) Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. Journal of the American College of Cardiology, 42, 991-997.
http://dx.doi.org/10.1016/S0735-1097(03)00919-7
[6] Fox, K.A., Steg, P.G., Eagle, K.A., Goodman, S.G., Anderson Jr., F.A., Granger, C.B., et al. (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. The Journal of the American Medical Association, 297, 1892-1900.
http://dx.doi.org/10.1001/jama.297.17.1892
[7] Anderson, J.L., Karagounis, L.A. and Califf, R.M. (1996) Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. American Journal of Cardiology, 78, 1-8.
http://dx.doi.org/10.1016/S0002-9149(96)00217-2
[8] O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey Jr., D.E., Chung, M.K., De Lemos, J.A., et al. (2013) ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61, e78-e140.
http://dx.doi.org/10.1016/j.jacc.2012.11.019
[9] Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343, 311-322.
[10] The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The New England Journal of Medicine, 329, 673-682.
http://dx.doi.org/10.1056/NEJM199309023291001
[11] Van De Werf, F., Adgey, J., Ardissino, D., Armstrong, P.W., Aylward, P., Barbash, G., et al. (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 doubleblind randomised trial. Lancet, 354, 716-722.
http://dx.doi.org/10.1016/S0140-6736(99)07403-6
[12] The European Myocardial Infarction Project Group (1993) Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The New England Journal of Medicine, 329, 383-389.
http://dx.doi.org/10.1056/NEJM199308053290602
[13] Steg, P.G., Bonnefoy, E., Chabaud, S., Lapostolle, F., Dubien, P.Y., Cristofini, P., et al. (2003) Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: Data from the CAPTIM randomized clinical trial. Circulation, 108, 2851-2856.
http://dx.doi.org/10.1161/01.CIR.0000103122.10021.F2
[14] Wallentin, L., Goldstein, P., Armstrong, P.W., Granger, C.B., Adgey, A.A., Arntz, H.R., et al. (2003) Efficacy and safety of tenecteplase in combination with the lowmolecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation, 108, 135-142.
http://dx.doi.org/10.1161/01.CIR.0000081659.72985.A8
[15] Gibson, C.M., Cannon, C.P., Murphy, S.A., Marble, S.J., Barron, H.V. and Braunwald, E. (2002) Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation, 105, 1909-1913.
http://dx.doi.org/10.1161/01.CIR.0000014683.52177.B5
[16] Gershlick, A.H., Stephens-Lloyd, A., Hughes, S., Abrams, K.R., Stevens, S.E., Uren, N.G., et al. (2005) Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. The New England Journal of Medicine, 353, 2758-2768.
http://dx.doi.org/10.1056/NEJMoa050849
[17] Wijeysundera, H.C., Vijayaraghavan, R., Nallamothu, B.K., Foody, J.M., Krumholz, H.M., Phillips, C.O., et al. (2007) Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: A meta-analysis of randomized trials. Journal of the American College of Cardiology, 49, 422-430.
http://dx.doi.org/10.1016/j.jacc.2006.09.033
[18] Keeley, E.C., Boura, J.A. and Grines, C.L. (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet, 361, 13-20.
http://dx.doi.org/10.1016/S0140-6736(03)12113-7
[19] Kindermann, M., Adam, O., Werner, N. and Bohm, M. (2007) Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clinical Research in Cardiology, 96, 767-786. http://dx.doi.org/10.1007/s00392-0591-z
[20] The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The New England Journal of Medicine, 329, 1615-1622.
http://dx.doi.org/10.1056/NEJM199311253292204
[21] Ohman, E.M., Califf, R.M., Topol, E.J., Candela, R., Abbottsmith, C., Ellis, S., et al. (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation, 82, 781-791. http://dx.doi.org/10.1161/01.CIR.82.3.781
[22] Gibson, C.M., Karha, J., Murphy, S.A., James, D., Morrow, D.A., Cannon, C.P., et al. (2003) Early and longterm clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. Journal of the American College of Cardiology, 42, 7-16.
http://dx.doi.org/10.1016/S0735-1097(03)00506-0
[23] Hudson, M.P., Granger, C.B., Topol, E.J., Pieper, K.S., Armstrong, P.W., Barbash, G.I., et al. (2001) Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation, 104, 1229-1235.
http://dx.doi.org/10.1161/hc3601.095717
[24] Gore, J.M., Granger, C.B., Simoons, M.L., Sloan, M.A., Weaver, W.D., White, H.D., et al. (1995) Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation, 92, 2811-2818.
http://dx.doi.org/10.1161/01.CIR.92.10.2811
[25] Cannon, C.P., Bahit, M.C., Haugland, J.M., Henry, T.D., Schweiger, M.J., McKendall, G.R., et al. (2002) Underutilization of evidence-based medications in acute ST elevation myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 registry. Critical Pathways in Cardiology, 1, 44-52.
http://dx.doi.org/10.1097/00132577-200203000-00007
[26] Pinto, D.S., Kirtane, A.J., Nallamothu, B.K., Murphy, S.A., Cohen, D.J., Laham, R.J., et al. (2006) Hospital delays in reperfusion for ST-elevation myocardial infarction: Implications when selecting a reperfusion strategy. Circulation, 114, 2019-2025.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.638353
[27] Nallamothu, B.K. and Bates, E.R. (2003) Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: Is timing (almost) everything? American Journal of Cardiology, 92, 824-826.
http://dx.doi.org/10.1016/S0002-9149(03)00891-9
[28] De Luca, G., Suryapranata, H., Ottervanger, J.P. and Antman, E.M. (2004) Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. Circulation, 109, 1223-1225.
http://dx.doi.org/10.1161/01.CIR.0000121424.76486.20
[29] Hutchison, A.W., Malaiapan, Y., Jarvie, I., Barger, B., Watkins, E., Braitberg, G., et al. (2009) Prehospital 12-lead ECG to triage ST-elevation myocardial infarction and emergency department activation of the infarct team significantly improves door-to-balloon times: Ambulance Victoria and MonashHEART Acute Myocardial Infarction (MonAMI) 12-lead ECG project. Circulation: Cardiovascular Interventions, 2, 528-534.
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.109.892372
[30] Andersen, H.R., Nielsen, T.T., Rasmussen, K., Thuesen, L., Kelbaek, H., Thayssen, P., et al. (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. The New England Journal of Medicine, 349, 733-742.
http://dx.doi.org/10.1056/NEJMoa025142
[31] Montalescot, G., Zeymer, U., Silvain, J., Boulanger, B., Cohen, M., Goldstein, P., et al. (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial. Lancet, 378, 693-703.
http://dx.doi.org/10.1016/S0140-6736(11)60876-3
[32] Navarese, E.P., De Luca, G., Castriota, F., Kozinski, M., Gurbel, P.A., Gibson, C.M., et al. (2011) Low-molecularweight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis. Journal of Thrombosis and Haemostasis, 9, 1902-1915.
http://dx.doi.org/10.1111/j.1538-7836.2011.04445.x
[33] Silvain, J., Beygui, F., Barthelemy, O., Pollack Jr., C., Cohen, M., Zeymer, U., et al. (2012) Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. BMJ, 344, e553.
http://dx.doi.org/10.1136/bmj.e553
[34] Stone, G.W., Witzenbichler, B., Guagliumi, G., Peruga, J.Z., Brodie, B.R., Dudek, D., et al. (2008) Bivalirudin during primary PCI in acute myocardial infarction. The New England Journal of Medicine, 358, 2218-2230.
http://dx.doi.org/10.1056/NEJMoa0708191
[35] Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine, 344, 1895-1903.
http://dx.doi.org/10.1056/NEJM200106213442503
[36] Antoniucci, D., Migliorini, A., Parodi, G., Valenti, R., Rodriguez, A., Hempel, A., Memisha, G. and Santoro, G.M. (2004) Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation, 109, 1704-1706.
http://dx.doi.org/10.1161/01.CIR.0000126284.40075.98
[37] Montalescot, G., Antoniucci, D., Kastrati, A., Neumann, F.J., Borentain, M., Migliorini, A., Boutron, C., Collet, J.P. and Vicaut, E. (2007) Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients’ data with longterm follow-up. European Heart Journal, 28, 443-449. http://dx.doi.org/10.1093/eurheartj/ehl472
[38] Stone, G.W., Grines, C.L., Cox, D.A., Garcia, E., Tcheng, J.E., Griffin, J.J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J.D., Rutherford, B.D. and Lansky, A.J. (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. New England Journal of Medicine, 346, 957-966.
http://dx.doi.org/10.1056/NEJMoa013404
[39] De Luca, G., Suryapranata, H., Stone, G.W., Antoniucci, D., Tcheng, J.E., Neumann, F.J., Van de Werf, F., Antman, E.M. and Topol, E.J. (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA, 293, 1759-1765.
http://dx.doi.org/10.1001/jama.293.14.1759
[40] Thiele, H., Wohrle, J., Neuhaus, P., Brosteanu, O., Sick, P., Prondzinsky, R., et al. (2010) Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. American Heart Journal, 159, 547-554. http://dx.doi.org/10.1016/j.ahj.2009.12.038
[41] Gu, Y.L., Kampinga, M.A., Wieringa, W.G., Fokkema, M.L., Nijsten, M.W., Hillege, H.L., Van den Heuvel, F.M., Tan, E.S., Pundziute, G., Van der Werf, R., Guyomi, S.H., Van der Horst, I.C.C., Zijlstra, F. and De Smet, B.J.G.L. (2010) Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarcttion undergoing primary percutaneous coronary intervention with thrombus aspiration: The comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation, 122, 2709-2717.
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.002741
[42] Valgimigli, M., Percoco, G., Malagutti, P., Campo, G., Ferrari, F., Barbieri, D., Cicchitelli, G., McFadden, E.P., Merlini, F., Ansani, L., Guardigli, G., Bettini, A., Parrinello, G., Boersma, E. and Ferrari, R. (2005) Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA, 293, 2109-2117.
http://dx.doi.org/10.1001/jama.293.17.2109
[43] Gibson, C.M., Kirtane, A.J., Murphy, S.A., Rohrbeck, S., Menon, V., Lins, J., et al. (2006) Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American Heart Journal, 152, 668-675.
http://dx.doi.org/10.1016/j.ahj.2006.06.003
[44] Piscione, F., Piccolo, R., Cassese, S., Galasso, G., De Rosa, R., D’Andrea, C. and Chiariello, M. (2010) Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: A meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention, 5, 853-860. http://dx.doi.org/10.4244/EIJV5I7A143
[45] Svilaas, T., Vlaar, P.J., van der Horst, I.C., Diercks, G.F., de Smet, B.J., van den Heuvel, A.F., Anthonio, R.L., Jessurun, G.A., Tan, E.S., Suurmeijer, A.J.H. and Zijlstra, F. (2008) Thrombus aspiration during primary percutaneous coronary intervention. New England Journal of Medicine, 358, 557-567.
http://dx.doi.org/10.1056/NEJMoa0706416
[46] De Luca, G., Dudek, D., Sardella, G., Marino, P., Chevalier, B. and Zijlstra, F. (2008) Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A metaanalysis of randomized trials. European Heart Journal, 29, 3002-3010.
http://dx.doi.org/10.1093/eurheartj/ehn389
[47] Eikelboom, J.W., Mehta, S.R., Anand, S.S., Xie, C., Fox, K.A. and Yusuf, S. (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114, 774-782.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.612812
[48] Manoukian, S.V., Feit, F., Mehran, R., Voeltz, M.D., Ebrahimi, R., Hamon, M., Dangas, G.D., Lincoff, A.M., White, H.D., Moses, J.W., King III, S.B., Ohman, E.M. and Stone, G.W. (2007) Impact of major bleeding on 30day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. Journal of the American College of Cardiology, 49, 1362-1368. http://dx.doi.org/10.1016/j.jacc.2007.02.027
[49] Mehran, R., Lansky, A.J., Witzenbichler, B., Guagliumi, G., Peruga, J.Z., Brodie, B.R., Dudek, D., Kornowski, R., Hartmann, F., Gersh, B.J., Pocock, S.J., Wong, S.C., Nikolsky, E., Gambone, L., Vandertie, L., Parise, H., Dangas, G.D. and Stone, G.W. (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet, 374, 1149-1159.
http://dx.doi.org/10.1016/S0140-6736(09)61484-7
[50] Mehta, S.R., Boden, W.E., Eikelboom, J.W., Flather, M., Steg, P.G., Avezum, A., et al. (2008) Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with STand non-STsegment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation, 118, 2038-2046.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.789479
[51] Rao, S.V., Ou, F.S., Wang, T.Y., Roe, M.T., Brindis, R., Rumsfeld, J.S. and Peterson, E.D. (2008) Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: A report from the National cardiovascular data registry. JACC: Cardiovascular Interventions, 1, 379-386.
http://dx.doi.org/10.1016/j.jcin.2008.05.007
[52] Chase, A.J., Fretz, E.B., Warburton, W.P., Klinke, W.P., Carere, R.G., Pi, D., Berry, B. and Hilton, J.D. (2008) Association of the arterial access site at angioplasty with transfusion and mortality: The M.O.R.T.A.L study (Mortality benefit of reduced transfusion after percutaneous coronary intervention via the arm or leg). Heart, 94, 1019-1025. http://dx.doi.org/10.1136/hrt.2007.136390
[53] Valgimigli, M., Saia, F., Guastaroba, P., Menozzi, A., Magnavacchi, P., Santarelli, A., et al. (2012) Transradial versus transfemoral intervention for acute myocardial infarction: A propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell’Emilia-Romagna) multicenter registry. JACC: Cardiovascular Interventions, 5, 23-35.
http://dx.doi.org/10.1016/j.jcin.2011.08.018
[54] Mehta, S.R., Jolly, S.S., Cairns, J., Niemela, K., Rao, S.V., Cheema, A.N., et al. (2012) Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. Journal of the American College of Cardiology, 60, 2490-2499.
http://dx.doi.org/10.1016/j.jacc.2012.07.050
[55] Romagnoli, E., Biondi-Zoccai, G., Sciahbasi, A., Politi, L., Rigattieri, S., Pendenza, G., et al. (2012) Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in STElevation Acute Coronary Syndrome) study. Journal of the American College of Cardiology, 60, 2481-2419.
http://dx.doi.org/10.1016/j.jacc.2012.06.017
[56] Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy—III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. British Medical Journal, 308, 235-246.
http://dx.doi.org/10.1136/bmj.308.6923.235
[57] Sabatine, M.S., Cannon, C.P., Gibson, C.M., Lopez-Sendon, J.L., Montalescot, G., Theroux, P., Claeys, M.J., Cools, F., Hill, K.A., Skene, A.M., McCabe, C.H. and Braunwald, E. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New England Journal of Medicine, 352, 1179-1189.
http://dx.doi.org/10.1056/NEJMoa050522
[58] Chen, Z.M., Jiang, L.X., Chen, Y.P., Xie, J.X., Pan, H.C., Peto, R., et al. (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1607-1621. http://dx.doi.org/10.1016/S0140-6736(05)67660-X
[59] Mehta, S.R., Bassand, J.P., Chrolavicius, S., Diaz, R., Eikelboom, J.W., Fox, K.A., et al. (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. New England Journal of Medicine, 363, 930-942.
http://dx.doi.org/10.1056/NEJMoa0909475
[60] Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.J., Ardissino, D., De Servi, S., Murphy, S.A., Riesmeyer, J., Weerakkody, G., Gibson, C.M. and Antman, E.M. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357, 2001-2015. http://dx.doi.org/10.1056/NEJMoa0706482
[61] Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 361, 1045-1057.
http://dx.doi.org/10.1056/NEJMoa0904327
[62] Yusuf, S., Mehta, S.R., Chrolavicius, S., Afzal, R,, Pogue, J., Granger, C.B., et al. (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA, 295, 1519-1530.
http://dx.doi.org/10.1001/jama.295.13.joc60038
[63] Kastrati, A., Mehilli, J., Neumann, F.J., Dotzer, F., Ten Berg, J., Bollwein, H., et al. (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA, 295, 1531-1518. http://dx.doi.org/10.1001/jama.295.13.joc60034
[64] Stone, G.W., Bertrand, M.E., Moses, J.W., Ohman, E.M., Lincoff, A.M., Ware, J.H., et al. (2007) Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA, 297, 591-602.
http://dx.doi.org/10.1001/jama.297.6.591
[65] Clark, A.M., Hartling, L., Vandermeer, B. and McAlister, F.A. (2005) Meta-analysis: Secondary prevention programs for patients with coronary artery disease. Annals of Internal Medicine, 143, 659-672.
http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00010
[66] Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G. and Fox, K.K. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine, 345, 494-502.
http://dx.doi.org/10.1056/NEJMoa010746
[67] ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995) ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet, 345, 669-685.
http://dx.doi.org/10.1016/S0140-6736(95)90865-X
[68] Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P., et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349, 1893-1906.
http://dx.doi.org/10.1056/NEJMoa032292
[69] The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342, 821-828.
[70] Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., et al. (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology, 46, 425-431.
http://dx.doi.org/10.1016/j.jacc.2005.04.038
[71] Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 1495-1504. http://dx.doi.org/10.1056/NEJMoa040583
[72] Chen, Z.M., Pan, H.C., Chen, Y.P., Peto, R., Collins, R., Jiang, L.X., et al. (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1622-1632.
http://dx.doi.org/10.1016/S0140-6736(05)67661-1
[73] Dargie, H.J. (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet, 357, 1385-1390.
http://dx.doi.org/10.1016/S0140-6736(00)04560-8

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.